Actualités sur Savoir / Culture

European Society for Medical Oncology (ESMO)

ESMO Publishes New Position Paper on Supportive and Palliative Care

Lugano (ots) - ESMO, the leading professional organisation for medical oncology, published a position paper on supportive and palliative care, calling attention to the evolving and growing gap between the needs of cancer patients and the actual provision of patient-centred care. "New studies show that there may be a gap between what doctors think is important for patients, and what patients really need. With this position ...

Debiopharm International SA

The Japanese Cancer Association and Debiopharm Group Announce Winners of the 2017 JCA-Mauvernay Award

Lausanne (ots) - The 'JCA-Mauvernay Award 2017' is awarded to Doctors Yasuhiro Yamada and Hiroyoshi Nishikawa Debiopharm Group(TM) (Debiopharm - www.debiopharm.com), a Swiss-based global biopharmaceutical company, will be presenting the 'JCA-Mauvernay Award' on September 30 to Doctors Yasuhiro Yamada from the ...

Asate AG

2

Great Honor for Swiss Therapist in America. Snoring and Sleep Apnea Researcher Alex Suarez receives Ig-Nobel Prize

FDI World Dental Federation

FDI releases chairside guide for dentists with a focus on caries prevention

Debiopharm International SA

Debiopharm International SA Awarded $2.6 Million Grant from CARB-X to Support Development of Debio 1453 to fight drug resistant gonorrhea

Lausanne (ots) - Debiopharm, in collaboration with CARB-X, will utilize their state-of-the-art Fabiotics platform to develop novel therapeutics to combat drug-resistant gonorrhea. Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical ...

Sequana Medical AG

Sequana Medical Announces Publication of Results of Multicentre Randomized Controlled Study for the alfapump® vs. Large Volume Paracentesis for Refractory Ascites in Journal of Hepatology

Zurich (ots) - Sequana Medical AG ("Sequana Medical), a commercial stage medical device company and an innovator in the management of liver disease, announces the publication of a multicentre, randomized controlled trial in the Journal of Hepatology (http://ots.ch/w2er5). The study demonstrated that in patients with ...

Neovii Pharmaceuticals AG

Long-term outcomes after standard graft-versus-host disease (GvHD) prophylaxis in hemopoietic cell transplantation from matched unrelated donors strongly support the use of Grafalon® as standard therapy

ImmunoQure AG

ImmunoQure AG announces publication in Cell of naturally occurring patient-derived autoantibodies that limit human diseases

Düsseldorf (ots) - ImmunoQure AG, a German biotechnology company focused on the development of autoantibodies as therapeutics to treat common human diseases today announced the publication of data in the leading scientific journal Cell, demonstrating that such therapeutics can limit a variety of common human ...

TRON - Translational Oncology at University Medical Center Mainz

First preclinical proof-of-concept of mutation-based individualized cancer vaccine / Deep sequencing of immunogenic mutations may pave way for customized immunotherapy

Mainz (ots) - The Institute of Translational Oncology (TRON) together with BioNTech AG today announced the publication of a joint paper in the international journal Cancer Research that describes a new path for individually tailored cancer therapy. An interdisciplinary team of genome scientists and immunologists led ...

Qiagen N.V.

Home-based self-collected vaginal specimens detect more cervical lesions and cancers than cytology

Hilden, Germany, and Gaithersburg, Md. (ots) - Vaginal self-collection for Hybrid Capture®-based HPV testing increases screening coverage and is more sensitive than Pap smear shows a Mexican study published today online in the Lancet Promising findings published today online in the Lancet[i] from a community- based, randomized equivalence trial undertaken by public ...

European Renal Association - European Dialysis and Transplant Association (ERA-EDTA)

ERA-EDTA congress 2011: Late Breaking Clinical Trials I / RAVE study: In ANCA-associated vasculitis rituximab is just as effective and safe as standard therapy

Prague, Czech Republic (ots) - The randomised, double-blind, placebo-controlled multi-centre study (abstract no. 2511) investigated the efficacy and safety of the monoclonal antibody rituximab (RTX) in 197 ANCA-associated vasculitis (AAV) patients. This study showed that in patients with severe AAV a single course ...

European Renal Association - European Dialysis and Transplant Association (ERA-EDTA)

XLVIII ERA-EDTA Congress in Prague from 23 June to 26 June 2011

Prag (ots) - The congress of the ERA-EDTA (European Renal Association and European Dialysis and Transplant Association) is the biggest congress in Europe on nephrology and renal replacement therapy. You are cordially invited to attend this Congress. The Opening Press Conference will be held on Thursday 23rd June, 11 am (Corinthia Hotel). Topic: Can the high level of cardiovascular risk among the European population be ...